STOCK MARKETING INC PRESENTS :
(OTCBB: FORC) Force Energy Corp.
(NASDAQ: FSTR) Foster (L.B.) Co.
(NASDAQ: FULT) Fulton Financial Corp.
(NASDAQ: GENZ) enzyme Corp.
(NASDAQ: GHDX) Genomic Health, Inc.
www.StockMarketingInc.com
To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com
Email us!! info@StockMarketingInc.com OR CALL 1-866-583-8960
(OTCBB: FORC) Force Energy Corp.
BREAKING NEWS!!
Force Energy Corp. Announces $5 Million Equity Financing
DENVER, COLORADO, Oct 7, 2009 Force Energy Corp. (OTCBB:FORC)(FRANKFURT:FC2) (hereafter "Force", "the Company"), is pleased to announce that the company has entered into a financing agreement with Banque SCS Alliance, whereby the Swiss based banking group will invest up to $5 million into Force Energy Corp.
The financing agreement is equity based and market condition dependent. The agreement may be receded by either party with 30 days notice. Funds will be used to advance drilling activities on the Diamond Springs Prospect as well as for general working capital and investment purposes. Force Energy has secured only traditional equity financing.
"We are pleased to have Bank SCS Alliance in our corner." Said Rahim Rayani, President & CEO of Force Energy Corp. "This financing agreement will allow the Company to execute on our plans to explore and develop the Diamond Springs Prospect."
The securities offered have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent a registration or an applicable exemption from the registration requirements.
About Force Energy Corp.
Force Energy Corp. is an Oil & Gas Exploration and Development Company based in Denver, CO with a focus on Wyoming. Using a geology-based methodology, the US Geological Survey estimate a mean of 2.4 trillion cubic feet of undiscovered natural gas and a mean of 41 million barrels of undiscovered oil in the Wind River Basin Province of Wyoming. Force Energy Corp. has acquired 75% working interest in the Diamond Springs Prospect located within this prolific area. The Company's shares are publicly traded on the OTCBB under the ticker symbol FORC.
On behalf of the Board of Directors
FORCE ENERGY CORP.
Legal Notice Regarding Forward-Looking Statements
Legal Notice Regarding Forward-Looking Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined, and assumptions of management. Forward looking statements are generally, but not always, identified by the words "expects", "plans", "anticipates", "has", "believes", "intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective", and similar expressions or that events or conditions "will", "would", "may", "can", "could" or "should" occur. Information concerning oil or natural gas reserve estimates may also be deemed to be forward looking statements, as it constitutes a prediction of what might be found to be present when and if a project is actually developed.
Actual results may differ materially from those currently anticipated due to a number of factors beyond the reasonable control of the Company. It is important to note that actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include misinterpretation of data, inaccurate estimates of oil and natural gas reserves, the uncertainty of the requirements demanded by environmental agencies, the Company's ability to raise financing for operations, breach by parties with whom we have contracted, inability to maintain qualified employees or consultants because of compensation or other issues, competition for equipment, inability to obtain drilling permits, potential delays or obstacles in drilling operations and interpreting data, the likelihood that no commercial quantities of oil or gas are found or recoverable, and our ability to participate in the exploration of, and successful completion of development programs on all aforementioned prospects and leases. Additional information on risks for the Company can be found in filings on Edgar of other junior oil and gas exploration companies with the US Securities and Exchange Commission.
SOURCE: Force Energy Corp.
CONTACT: Investor Relations Force Energy Corp.
Rahim Rayani, President & CEO 1-866-953-FORC (3672) ir@forceenergycorp.com www.forceenergycorp.com
(NASDAQ: FSTR) Foster (L.B.) Co.
BREAKING NEWS!!
L.B. Foster Receives $2.7 Million Rail Products Contract for Pittsburgh North Shore Connector
Port Authority of Allegheny County Looks to Local Rail and Construction Products Firm for Transit Materials
PITTSBURGH, Oct 06, 2009 L.B. Foster Company (Nasdaq: FSTR) of Pittsburgh, PA has received a $2.7 million contract to supply a wide ranging package of rail products to the Allegheny County Port Authority Light Rail System. L.B. Foster is providing rail fasteners, trackwork and new rail for construction of the 1.2 mile North Shore Connector. This light rail transportation corridor will travel in two bored tunnels beneath the Allegheny River to connect Pittsburgh's city center (Gateway Subway Station under Stanwix Street) with North Shore neighborhoods and attractions.
(Photo: http://www.newscom.com/cgi-bin/prnh/20091006/NE88027 )
"Our transit products team is providing field-proven L.B. Foster direct fixation fasteners and special trackwork to the contractor, Delta Railroad Construction, for this important project," said Ben Leidy, Pittsburgh Rail Sales Representative with locally headquartered L.B. Foster Company. "We count on suppliers like L.B. Foster when we require a full range of quality rail products for major transit projects, such as the North Shore Connector," said Larry Laurello, President, Delta Railroad Construction of Ashtabula, OH. L.B. Foster is also supplying 470 tons of new 115lb rail and trackwork items.
Final delivery of L.B. Foster materials is scheduled for late 2010 and train service should begin in 2011.
About L.B. Foster Company
L.B. Foster Company supplies transportation, construction, utility, recreation and agriculture markets with the materials necessary to build and maintain North America's infrastructure. The Rail Products Group of L.B. Foster Company markets new rail and accessories, used rail (relay rail), crane rail, direct fixation fastener systems, conductor rail systems, rail boot systems, two-block tie systems, insulated rail joints, rail lubrication systems, trackwork materials, rapid response/emergency track panels and experienced professional rail project management services nationwide. Visit our new website: www.lbfoster.com
L.B. Foster Company Sales and Media Contacts:
Ben Leidy, Sales Representative, L.B. Foster Rail Group 412.928.3433 bleidy@lbfosterco.com
Jake Fuellhart, L.B. Foster Marketing Communications Manager 412.928.5645 jfuellhart@lbfosterco.com
(NASDAQ: FULT) Fulton Financial Corp.
BREAKING NEWS!!
Fulton Financial Corporation Announces Dates for Third Quarter Earnings Release and Conference Call/Webcast
LANCASTER, PA, Oct 06, 2009 Fulton Financial Corporation (NASDAQ: FULT) today announced that it will distribute its third quarter earnings news release and accompanying charts on Tuesday, October 20 at approximately 4:30 p.m. Eastern Time.
The Corporation will host its quarterly conference call with analysts who cover the company on Wednesday, October 21 at 10 a.m. Eastern Time. R. Scott Smith, Jr., chairman and CEO, will host the call. He will be joined by E. Philip Wenger, president and COO, and by Charles J. Nugent, senior executive vice president and CFO.
The live webcast of this call can be heard by going to Fulton Financial Corporation's website, www.fult.com, selecting the Investor Information tab and clicking on the link to the webcast. The webcast will be archived on the company's website for 30 days following the call.
Fulton Financial Corporation is a financial holding company that operates 270 banking offices in Pennsylvania, Maryland, Delaware, New Jersey and Virginia through the following affiliates: Fulton Bank, N.A., Lancaster, PA; Swineford National Bank, Middleburg, PA; Lafayette Ambassador Bank, Easton, PA; FNB Bank, N.A., Danville, PA; Delaware National Bank, Georgetown, DE; The Bank, Woodbury, NJ; Skylands Community Bank, Hackettstown, NJ; and The Columbia Bank, Columbia, MD.
The Corporation's additional financial services providers include Fulton Financial Advisors, N.A., Lancaster, PA; Fulton Insurance Services Group, Inc., Lancaster, PA; and Dearden, Maguire, Weaver and Barrett, LLC, West Conshohocken, PA. Residential mortgage lending is offered by all banks through Fulton Mortgage Company.
Additional information on Fulton Financial Corporation is available on the Internet at www.fult.com.
2009
CONTACT: Laura Wakeley 717-291-2616
(NASDAQ: GENZ) enzyme Corp.
BREAKING NEWS!!
Genzyme Receives FDA Complete Response Letter for Clolar
CAMBRIDGE, Mass., Oct 06, 2009 Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar(R) (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled clinical study be conducted for label expansion of Clolar in this indication.
In September, the FDA Oncologic Drugs Advisory Committee voted 9 to 3 that data from a randomized, controlled trial was necessary to establish the efficacy and safety of Clolar in the proposed adult AML indication. Genzyme had sought approval to expand the indication based on the findings from a single-arm trial in an adult AML population.
Genzyme intends to request a meeting with the FDA to discuss the optimal path forward, including what additional or ongoing studies may satisfy regulatory requirements.
Genzyme is conducting a randomized, placebo-controlled Phase 3 trial (CLASSIC I) comparing clofarabine in combination with cytarabine to cytarabine alone in relapsed and refractory adult AML patients 55 years old or older. The trial continues to exceed patient accrual expectations, and results are expected in 2011. Clofarabine, which is an approved agent in the treatment of relapsed or refractory pediatric acute lymphoblasic leukemia (ALL) after at least two prior regimens, is also being investigated in clinical trials by many of the leading AML experts and major cooperative leukemia investigation groups in the United States and Europe.
About Clolar
Clolar is currently approved for pediatric ALL patients who have relapsed or have refractory disease after at least two prior regimens. Clolar has Orphan Drug designation for AML and pediatric ALL, and seven years of market exclusivity in the United States for relapsed/refractory pediatric ALL. The FDA also granted six months of extended market exclusivity to Clolar under the Best Pharmaceuticals for Children Act. For more information about Clolar, please call 1-800-RX CLOLAR or visit www.CLOLAR.com.
About Genzyme
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.
With many established products and services helping patients in nearly 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.
This press release contains forward-looking statements regarding Genzyme's business plans and strategies, including without limitation its expectations for discussions with the FDA and the availability of data from the company's phase 3 study for Clolar. These risks and uncertainties include, among others: the FDA's decisions regarding a path forward for the possible approval of Clolar to treat older adult patients with acute myeloid leukemia; the actual safety and efficacy of Clolar for the indications in which it is being tested; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10Q for the quarter ended June 30, 2009. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.
Genzyme(R) and Clolar(R) are registered trademarks of Genzyme Corporation or its subsidiaries. All rights reserved.
Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.
SOURCE: Genzyme Corporation
CONTACT:
Genzyme Corporation Media Contact: John Lacey, 617-768-6690 857-222-8589 (mobile) john.lacey@genzyme.com or Investor Contact: Patrick Flanigan, 617-768-6563
(NASDAQ: GHDX) Genomic Health, Inc.
BREAKING NEWS!!
Genomic Health to Present Studies at the American Society of Clinical Oncology 2009 Breast Cancer Symposium
REDWOOD CITY, Calif., Oct 06, 2009 Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from two studies at the American Society of Clinical Oncology (ASCO) 2009 Breast Cancer Symposium, taking place October 8 through October 10 at the San Francisco Marriott in San Francisco, California. Both studies analyze Oncotype DX(R), the company's multi-gene expression test that physicians use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.
Presentation details are as follows (all times are Pacific Daylight Time):
- Friday, October 9 (12:30 p.m. - 1:30 p.m. PT and 5:30 p.m. - 7 p.m. PT) Poster Board #A15 Poster presentation: "Biopsy Cavities in Breast Cancer Specimens: Impact on Gene Expression Profiles and Recurrence Risk Assessment" Presenter: Rick Baehner, M.D., Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco Location: Golden Gate Hall
- Friday, October 9 (12:30 p.m. - 1:30 p.m. PT and 5:30 p.m. - 7 p.m. PT) Poster Board #A19 Poster Presentation: "A Study of the Oncotype DX(R) Recurrence Score(R) as a Prognostic Factor in Early Stage Breast Cancer in the Japanese Population" Presenter: Masakazu Toi, M.D., Ph.D, Department of Surgery, Graduate School of Medicine, Kyoto University Location: Golden Gate Hall
About Oncotype DX(R)
The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer assay has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. As of May 2009, more than 8,000 physicians had ordered more than 100,000 tests in over 40 countries, and both Medicare and private health plans covering over 90 percent of U.S. insured lives, provide reimbursement for Oncotype DX through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit www.oncotypedx.com.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its Oncotype DX colon cancer test in early 2010. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.
About StockMarketingInc.com
StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by tockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
